Frontotemporal Dementia

The promise of tau aggregation inhibitors in dementia

Investigating TDP-43 pathology with cryptic exons

TDP-43 aggregation drives loss of UNC13A, a risk gene for ALS & FTD

de novo proteins generated from cryptic exon translation in ALS & FTD

Targeting cellular senescence in tauopathies

Next steps in dementia biomarkers

Anti-HMGB1 agents for the treatment of Alzheimer’s disease

Tau fibrils versus tau oligomers in neurotoxicity and neurodegeneration

Tau oligomers trigger astrocyte senescence in tauopathy models

Biomarkers for frontotemporal dementia

Plasma NfL as a biomarker for frontotemporal dementia

Diagnostic tools for neurodegenerative disease

Dipeptide repeat proteins and the NLRP3 inflammasome in FTD

Next steps for research into the NLRP3 inflammasome in dementia

Understanding tau proteostasis using iPSC

The role of phosphorylated tau in clinical trials